Lucia Gambuzza

Samantha Harding, MD, discusses how ultra-widefield imaging reduces dilation needs and improves diagnosis in paediatric eye care.

Sessions at the 1-4 October Vienna congress address GA patient selection, AI-based functional prediction, imaging biomarkers, and surgical intervention.

Ashraf Ahmad, MD, explains what's driving rising dry eye rates and why eyelid evaluation is often overlooked.

At ESCRS 2026, Imane Tarib, MD discusses fostering inclusive ophthalmology workplaces and mentorship for early-career surgeons.

The FDA has accepted Nanoscope's BLA for sonpiretigene isteparvovec in retinitis pigmentosa, backed by RESTORE and REMAIN trial data.

OT Roundup debuts with new ADHD ocular findings, a surgeon's own trifocal IOL journey, MOGENRY's FDA filing, and myopia policy news.

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence.

Bausch + Lomb's SeeLyra femtosecond laser platform, featuring live OCT imaging, has received CE mark approval for cataract, LASIK, and corneal procedures in Europe.

Majda Hadziahmetovic, MD, on MacTel neovascular warning signs, urgent referral, and how Encelto reshapes screening.

AMA resolution backs classifying myopia as a disease, aiming to expand insurance coverage for pediatric myopia control treatments.

ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.

Suzana Konjevoda, MD, presents data at ESCRS 2026 showing citicoline eye drops aid corneal nerve recovery post-cataract surgery.

Mingo-Botín, MD, PhD, discusses ESCRS 2026 data on an EDOF IOL in post-LASIK eyes vs non-LASIK controls.

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

A VR lens simulator used at InVision Eye Care lifted premium IOL conversion rates from 30%-35% to the mid-40s

Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.

Jay Chhablani, MD, on how MacTel eyes turn neovascular, when to refer, and what Encelto means for treatment.

Survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.

Esen Akpek, MD, weighs in on lifitegrast-perfluorohexyloctane phase 2 data and what it means for the drop's path to phase 3.

Antibiotic injection reduced endophthalmitis risk vs topical drops after cataract surgery, meta-analysis found.

Jonathan Gloth, MD, discusses how a dual Tie2/VEGF mechanism could reduce injection burden and the consequences of missed doses in wet AMD.

Japan designated gildeuretinol an orphan drug for Stargardt disease as the oral therapy enters phase 3 evaluation in the NORTHSTAR trial.

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

Bausch + Lomb advances dual-action dry eye drop to phase 3 and reports positive phase 1b data for TRPV1 antagonist BL1332

The over-the-counter lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

At WIO 2026, Durga Borkar, MD, discussed DAVIO2 trial results for EYP-1901 in wet AMD.